CD7 and neoplasm: To develop a bispecific CAR-T cell strategy to treat T-cell malignancies, we investigated and selected T-cell-pan markers CD5 and CD7 from a well-characterized tumor-specific antigen library, the safety and benefits of which for monovalent CAR-targeting have been established.9,25,26 CD5 is regularly expressed on normal T cells and ~85% of T-cell malignancies as well as some B-cell malignancies.